255 related articles for article (PubMed ID: 28062946)
1. Upregulated absorption of dietary palmitic acids with changes in intestinal transporters in non-alcoholic steatohepatitis (NASH).
Utsunomiya H; Yamamoto Y; Takeshita E; Tokumoto Y; Tada F; Miyake T; Hirooka M; Abe M; Kumagi T; Matsuura B; Ikeda Y; Hiasa Y
J Gastroenterol; 2017 Aug; 52(8):940-954. PubMed ID: 28062946
[TBL] [Abstract][Full Text] [Related]
2. Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients.
Enooku K; Tsutsumi T; Kondo M; Fujiwara N; Sasako T; Shibahara J; Kado A; Okushin K; Fujinaga H; Nakagomi R; Minami T; Sato M; Uchino K; Nakagawa H; Kondo Y; Asaoka Y; Tateishi R; Ueki K; Ikeda H; Yoshida H; Moriya K; Yotsuyanagi H; Kadowaki T; Koike K
J Gastroenterol; 2020 Feb; 55(2):227-243. PubMed ID: 31602526
[TBL] [Abstract][Full Text] [Related]
3. Intestinal SR-BI is upregulated in insulin-resistant states and is associated with overproduction of intestinal apoB48-containing lipoproteins.
Hayashi AA; Webb J; Choi J; Baker C; Lino M; Trigatti B; Trajcevski KE; Hawke TJ; Adeli K
Am J Physiol Gastrointest Liver Physiol; 2011 Aug; 301(2):G326-37. PubMed ID: 21546579
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36.
Hsieh J; Longuet C; Maida A; Bahrami J; Xu E; Baker CL; Brubaker PL; Drucker DJ; Adeli K
Gastroenterology; 2009 Sep; 137(3):997-1005, 1005.e1-4. PubMed ID: 19482026
[TBL] [Abstract][Full Text] [Related]
5. Rapid alternative absorption of dietary long-chain fatty acids with upregulation of intestinal glycosylated CD36 in liver cirrhosis.
Yamamoto Y; Hiasa Y; Murakami H; Ikeda Y; Yamanishi H; Abe M; Matsuura B; Onji M
Am J Clin Nutr; 2012 Jul; 96(1):90-101. PubMed ID: 22648712
[TBL] [Abstract][Full Text] [Related]
6. The mechanism of increased intestinal palmitic acid absorption and its impact on hepatic stellate cell activation in nonalcoholic steatohepatitis.
Hanayama M; Yamamoto Y; Utsunomiya H; Yoshida O; Liu S; Mogi M; Matsuura B; Takeshita E; Ikeda Y; Hiasa Y
Sci Rep; 2021 Jun; 11(1):13380. PubMed ID: 34183709
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis.
Yamada K; Mizukoshi E; Sunagozaka H; Arai K; Yamashita T; Takeshita Y; Misu H; Takamura T; Kitamura S; Zen Y; Nakanuma Y; Honda M; Kaneko S
Liver Int; 2015 Feb; 35(2):582-90. PubMed ID: 25219574
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice.
Yamamoto T; Nakade Y; Yamauchi T; Kobayashi Y; Ishii N; Ohashi T; Ito K; Sato K; Fukuzawa Y; Yoneda M
World J Gastroenterol; 2016 Feb; 22(8):2512-23. PubMed ID: 26937139
[TBL] [Abstract][Full Text] [Related]
9. Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis.
Chatterjee A; Basu A; Das K; Singh P; Mondal D; Bhattacharya B; Roychoudhury S; Majumder PP; Chowdhury A; Basu P
Ann Hepatol; 2020; 19(5):472-481. PubMed ID: 32682086
[TBL] [Abstract][Full Text] [Related]
10. CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis.
Zhao L; Zhang C; Luo X; Wang P; Zhou W; Zhong S; Xie Y; Jiang Y; Yang P; Tang R; Pan Q; Hall AR; Luong TV; Fan J; Varghese Z; Moorhead JF; Pinzani M; Chen Y; Ruan XZ
J Hepatol; 2018 Sep; 69(3):705-717. PubMed ID: 29705240
[TBL] [Abstract][Full Text] [Related]
11. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.
Miquilena-Colina ME; Lima-Cabello E; Sánchez-Campos S; García-Mediavilla MV; Fernández-Bermejo M; Lozano-Rodríguez T; Vargas-Castrillón J; Buqué X; Ochoa B; Aspichueta P; González-Gallego J; García-Monzón C
Gut; 2011 Oct; 60(10):1394-402. PubMed ID: 21270117
[TBL] [Abstract][Full Text] [Related]
12. Intracellular and extracellular miRNome deregulation in cellular models of NAFLD or NASH: Clinical implications.
Di Mauro S; Ragusa M; Urbano F; Filippello A; Di Pino A; Scamporrino A; Pulvirenti A; Ferro A; Rabuazzo AM; Purrello M; Purrello F; Piro S
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1129-1139. PubMed ID: 27756518
[TBL] [Abstract][Full Text] [Related]
13. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.
Linden MA; Sheldon RD; Meers GM; Ortinau LC; Morris EM; Booth FW; Kanaley JA; Vieira-Potter VJ; Sowers JR; Ibdah JA; Thyfault JP; Laughlin MH; Rector RS
J Physiol; 2016 Sep; 594(18):5271-84. PubMed ID: 27104887
[TBL] [Abstract][Full Text] [Related]
14. Development and physiological regulation of intestinal lipid absorption. I. Development of intestinal lipid absorption: cellular events in chylomicron assembly and secretion.
Black DD
Am J Physiol Gastrointest Liver Physiol; 2007 Sep; 293(3):G519-24. PubMed ID: 17495031
[TBL] [Abstract][Full Text] [Related]
15. Serum-inducible protein (IP)-10 is a disease progression-related marker for non-alcoholic fatty liver disease.
Wada N; Takaki A; Ikeda F; Yasunaka T; Onji M; Nouso K; Nakatsuka A; Wada J; Koike K; Miyahara K; Shiraha H; Yamamoto K; Okada H
Hepatol Int; 2017 Jan; 11(1):115-124. PubMed ID: 27826704
[TBL] [Abstract][Full Text] [Related]
16. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
[TBL] [Abstract][Full Text] [Related]
17. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
18. Elevated free cholesterol in a p62 overexpression model of non-alcoholic steatohepatitis.
Simon Y; Kessler SM; Gemperlein K; Bohle RM; Müller R; Haybaeck J; Kiemer AK
World J Gastroenterol; 2014 Dec; 20(47):17839-50. PubMed ID: 25548482
[TBL] [Abstract][Full Text] [Related]
19. Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model.
Nozaki Y; Fujita K; Wada K; Yoneda M; Kessoku T; Shinohara Y; Imajo K; Ogawa Y; Nakamuta M; Saito S; Masaki N; Nagashima Y; Terauchi Y; Nakajima A
BMC Gastroenterol; 2015 Apr; 15():42. PubMed ID: 25881230
[TBL] [Abstract][Full Text] [Related]
20. The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease.
Okushin K; Tsutsumi T; Enooku K; Fujinaga H; Kado A; Shibahara J; Fukayama M; Moriya K; Yotsuyanagi H; Koike K
J Gastroenterol; 2016 Aug; 51(8):808-18. PubMed ID: 26601667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]